URO TODAY: Benign prostatic hyperplasia patients in whom prostate cancer is suspected and who have urination problems, with a previously negative biopsy result, can undergo transurethral resection of the prostate, which treats bladder outlet obstruction and gives early diagnosis of prostate cancer. READ MORE>
Posts Tagged ‘Enlarged prostate’
TURP is useful for diagnosing early stage prostate cancer
Posted in Diagnosis, Enlarged prostate, PROSTATE CANCER, PROSTATE RESEARCH, Trans-urethral re-section, Urination, tagged benign prostatic hyperplasia, Biopsy, bladder outlet obstruction, cancer research, catheter, early diagnosis of prostate cancer, Enlarged prostate, Incontinence, lower urinary tract symptoms, previously negative biopsy, prostablog, prostate, prostate blog, PROSTATE CANCER, quality of life, transurethral resection, Urination, urination problems, URO TODAY on June 20, 2010| Leave a Comment »
Combo drug for prostatic hyperplasia in men with enlarged prostate
Posted in Enlarged prostate, PROSTATE CANCER, tagged cancer research, catheter, Enlarged prostate, GlaxoSmithKline, Jalyn, PHARMA TIMES, prostablog, prostate, prostate blog, prostatic hyperplasia on June 17, 2010| Leave a Comment »
PHARMA TIMES: US regulators have approved GlaxoSmithKline’s combination drug, Jalyn, to treat symptomatic benign prostatic hyperplasia in men with an enlarged prostate. READ MORE>
Is ‘opt out’ the answer to conundrum over whether or not men should be offered prostate cancer tests?
Posted in PROSTATE CANCER, PSA tests, Screening debate, tagged American Cancer Society, Biopsy, blood test, blood tests, Enlarged prostate, ethnic risk for prostate cancer, family history of prostate cancer, individual decision-making, medical checkups, Mike Scott, New Prostate Cancer Info-link, opt out, population-based testing, prostablog, prostate, prostate blog, prostate cancer screening, prostate-specific antigen, PSA, PSA test, Screening debate on October 12, 2009| Leave a Comment »
PROSTATE CANCER INFOLINK: Rather than having to ask for a prostate cancer test, men should be offered it but have the right to “opt out”. READ MORE>
That’s the novel view put forward by top US prostate cancer website New Prostate Cancer Infolink, whose administrator, Mike Scott, writes:
The way we see this is that men should have an “opt out” clause that allows them not to get tested for prostate cancer risk.
This is a very American option. One can argue over whether it is right or wrong, but it clearly leaves the decision in the hands of the individual.
His latest blog looks at the somewhat ambivalent views of the American Cancer Society:
It would…be helpful, if the ACS’s chief medical officer would be so kind as to articulate the ACS’s official position with clarity, as opposed to his tendency to articulate his personal opinion about “screening” (ie, mass, population-based testing of everyone), so that the average man in the street was getting a clear message about what the ACS actually does recommend.
Scott’s view is:
…the following people should absolutely be getting PSA tests and physical exams as a means of assessing their risk for clinically significant prostate cancer starting somewhere between 40 and 50 years of age depending on their risk factors:
- Any man with a family history of prostate cancer
- Any man with an ethnic risk for prostate cancer (specifically including African Americans)
- Any man who requests such tests
- Any man who asks his physician to decide whether he should get such tests for him
In addition:
- Every man should be having a conversation with his doctor to discuss the relative risks and benefits of testing to detect possible risk for prostate cancer.
Prostate size makes no difference to outcome of radical prostatectomy
Posted in PROSTATE CANCER, PROSTATE RESEARCH, Radical prostatectomy, tagged cancer research, Enlarged prostate, functional results, New York, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate size, prostate treatment, prostate treatment debate, prostatectomy, Radical prostatectomy, Sloan Kettering, technical difficulty on September 13, 2009| Leave a Comment »
ABC NEWS: Prostate size affects the technical difficulty of radical prostatectomy but not the functional results. READ MORE>
NZ government issues new guidelines to GPs on how to handle prostate cancer patients
Posted in Diagnosis, Govt prostate policy, Maori mortality, PROSTATE CANCER, PSA tests, Public health system, Screening debate, Uncategorized, tagged an enlarged, blood in urine, blood test, blood tests, care and mortality disparities b, detection, digital diagnosis, digital examination, digital rectal examination, Enlarged prostate, Erectile function, European Kiwis., frequency, GP advice on prostate, Guidelines for investigation, hesitancy, how to handle prostate symptoms, lower urinary tract symptoms, macroscopic haematuria, Maori, nocturia, NZ Guidelines Group, NZ Ministry of Health, Pacific people, Parliamentary inquiry into prostate cancer, population-based screening, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer screening, prostate cancer treatments, prostate treatment debate, prostate-specific antigen, PSA, PSA test, referral and reducing ethnic disparities, smooth prostate, Suspected Cancer in Primary Care on September 11, 2009| Leave a Comment »
PROSTABLOG NZ: New guidelines for general practitioners on how to handle men presenting with possible symptoms of prostate cancer (and other cancers) were released today by the NZ Ministry of Health. READ MORE> and HERE (summary)>
The advice is contained in a 174-page report from the Ministry-backed NZ Guidelines Group called Suspected Cancer in Primary Care – Guidelines for investigation, referral and reducing ethnic disparities, which sets out background data and guiding principles on a range of cancers.
The report avoids getting into population-based screening – a major issue in detecting prostate cancer – saying:
Cancer screening, health promotion and prevention, case-finding in asymptomatic people, recurrence of a previous cancer and metastatic cancer were beyond the guideline scope and therefore are not included.
However, it does relent a little in the section on ethnicity and cancer treatment disparity:
Addressing the issue of cancer screening is outside the broad scope of this guideline. However, because of the impact that screening uptake can potentially have on disease outcomes, it is briefly included as part of this disparity chapter.
In the section on prostate cancer, it outlines the following advice for GPs seeing patients:
- A man presenting with macroscopic haematuria (blood in urine) should be referred urgently to a specialist;
- A man found to have an enlarged, smooth prostate on digital rectal examination and a normal PSA should only be referred to a specialist if they have macroscopic haematuria;
- An older man presenting with lower urinary tract symptoms (frequency, hesitancy, nocturia) should be recommended to have a digital rectal examination and a PSA test.
Men with erectile dysfunction are excluded from the referral guidelines.
The report also contains the latest data on cancer trends and explores in some depth the detection, care and mortality disparities between Maori, Pacific people and European Kiwis.
On the page listing organisations that endorse the report (so presumably have seen it already), the Cancer Society of NZ (which opposes population-based prostate cancer screening) is included – but not the Prostate Cancer Foundation of NZ (which supports it).
The report comes just a week before the Government’s Parliamentary inquiry into prostate cancer detection and treatment, which will hear its first submissions on Wednesday.
Size doesn’t matter – in case of recovery from radical prostatectomy
Posted in Biochemical recurrence, PROSTATE CANCER, PROSTATE RESEARCH, Radical prostatectomy, tagged Biochemical recurrence, blood loss, cancer research, Enlarged prostate, larger prostate size, operaion time, positive surgical margins, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate size, prostate treatment, prostatectomy, Radical prostatectomy, smaller glands, surgery, URO TODAY on August 27, 2009| Leave a Comment »
URO TODAY: Prostate size does not appear to affect biochemical recurrence after radical prostatectomy. However, estimated blood loss and operation time increased with larger prostate size, and positive surgical margins are more often observed in smaller glands. READ MORE>
New drug for treating benign prostatic hyperplasia enters phase 2 clinical trial in US
Posted in Enlarged prostate, PROSTATE CANCER, Treatment news, tagged Aptocine(TM) (talaporfin sodium), benign prostatic hyperplasia, BIO-MEDICINE, Enlarged prostate, innovative targeted drug treatment, Light Sciences Oncology Inc., Phase 2 clinical trial, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate on August 20, 2009| Leave a Comment »
BIO-MEDICINE: The first patients have entered a Phase 2 clinical trial of a innovative targeted drug treatment, Aptocine(TM) (talaporfin sodium), for benign prostatic hyperplasia (enlarged prostate). READ MORE>
Less invasive implant gives better results in treating post-prostate surgery incontinence
Posted in Incontinence, PROSTATE CANCER, PROSTATE RESEARCH, Radical prostatectomy, Treatment news, tagged Adjustable Continence Therapy, artificial urinary sphincter, benign prostatic hyperplasia, bulk injections, cancer research, comparison of treatments, Dutch study, Enlarged prostate, Inc., Incontinence, intrinsic sphincter deficiency, less invasive treatment, male sling, minimally invasive urological implant, ProACT, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, prostatectomy, Radical prostatectomy, stress urinary incontinence, surgery, transurethral resection, Urination, URO TODAY, urology, Uromedica on July 18, 2009| Leave a Comment »
JULY 18: URO TODAY: In incontinence treatment called ProACT is a less invasive treatment compared to the standard artificial urinary sphincter, the male sling and bulk injections, a Dutch study shows. READ MORE>
Adjustable Continence Therapy (ProACT™) from Uromedica, Inc, is a minimally invasive urological implant designed to treat male patients who have stress urinary incontinence arising from intrinsic sphincter deficiency following radical prostatectomy for prostate cancer or transurethral resection of the prostate for benign prostatic hyperplasia.
Tadalafil once a day works on men with enlarged prostate and erectile dysfunction
Posted in Erectile function, PROSTATE RESEARCH, tagged Enlarged prostate, enlarged prostate (BPH), Erectile Dysfunction, erectile function improvements, general erectile dysfunction population, once-daily tadalafil, prostablog, prostate, prostate blog on July 13, 2009| Leave a Comment »
JULY 13: URO TODAY: Research shows that once-daily tadalafil is effective in men with erectile dysfunction and symptoms of enlarged prostate (BPH), with erectile function improvements comparable to those for the general erectile dysfunction population. READ MORE>